title: Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.
abstract: Terlipressin is a synthetic vasopressin analogue that is used in the treatment of bleeding esophageal varices and hepatorenal syndrome in patients with cirrhosis. Hepatorenal syndrome is a form of renal failure seen in patients with cirrhosis, with fatal outcomes. Ischemic adverse effects related to terlipressin are rarely observed. Herein, two cases who developed ischemic skin necrosis due to terlipressin usage are presented. Terlipressin therapy was started in two cirrhotic patients with presumptive hepatorenal syndrome. During the therapy, ecchymotic and necrotic changes were observed on the scrotal regions of both patients. Skin lesions were relieved after terlipressin therapy. Biopsy results were consistent with ischemia. Even if seen rarely, possible emergence of ischemic complications must be considered.
authors.affiliation: Department of Internal Medicine, Tokat Gaziosmanpaşa University, School of Medicine, Tokat, Turkey. turtasliyurt@hotmail.com
authors.forename: Türker
authors.initials: T
authors.lastname: Taşliyurt
authors.forename: Faruk
authors.initials: F
authors.lastname: Kutlutürk
authors.forename: Fikret
authors.initials: F
authors.lastname: Erdemır
authors.forename: Berna Murat
authors.initials: BM
authors.lastname: Yelken
authors.forename: Abdulkerim
authors.initials: A
authors.lastname: Yilmaz
authors.forename: Bünyamin
authors.initials: B
authors.lastname: Kisacik
authors.forename: Pelin
authors.initials: P
authors.lastname: Aytan
authors.forename: Reşit Doğan
authors.initials: RD
authors.lastname: Köseoğlu
mesh_terms: D000368:Aged; D006530:Hepatorenal Syndrome / Q000188:drug therapy*; D006801:Humans; D007511:Ischemia / Q000139:chemically induced* / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy; D008236:Lypressin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin